B. Abbuehl

发表

BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B

J. Windyga, B. Abbuehl, Andrea E. Hafeman, 2014, Expert review of hematology.

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.

B. Konkle, D. Bevan, O. Stasyshyn, 2015, Blood.

Improvement in health‐related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study

J. Epstein, J. Windyga, B. Abbuehl, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326 )

W. B. Knowlton, O. Stasyshyn, B. Abbuehl, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant factor IX (BAX326 ) in previously treated paediatric patients with haemophilia B: a prospective clinical trial

O. Stasyshyn, B. Abbuehl, T. Urasiński, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open‐label, uncontrolled, multicentre, phase III study

O. Stasyshyn, T. Lissitchkov, J. Windyga, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B

O. Stasyshyn, T. Lissitchkov, J. Windyga, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant Factor IX in Surgical Management of Hemostasis in Hemophilia B Patients: A Prospective Clinical Trial

T. Lissitchkov, J. Windyga, B. Abbuehl, 2016 .

Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A

O. Stasyshyn, R. Liesner, E. Mullins, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of pegylated full‐length recombinant factor VIII with extended half‐life for perioperative haemostasis in haemophilia A patients

B. Abbuehl, R. Gruppo, L. Griškevičius, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations

B. Konkle, Tetsuji Sato, T. Matsushita, 2017, International Journal of Hematology.

Clinical haemophilia Safe switching from a pdFIX ( Immunine ) to a rFIX ( Bax 3261 )

O. Stasyshyn, B. Abbuehl, M. Serban, 2014 .

Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A

M. Recht, A. Thompson, R. Liesner, 2012, Thrombosis and Haemostasis.

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

F. Horling, B. Reipert, B. Abbuehl, 2016 .

Characteristics of Patients without Bleeding in a Pivotal Trial of Extended Half-Life, Pegylated, Full-length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia A

R. Klamroth, M. Manco‐Johnson, B. Abbuehl, 2015 .

Joint Bleeding Patterns in Patients Treated Prophylactically with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855)

R. Klamroth, M. Manco‐Johnson, B. Abbuehl, 2015 .

An Integrated Analysis of Long Term Safety of an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia a

B. Konkle, T. Matsushita, B. Abbuehl, 2015 .